Vaxcyte, Inc. $PCVX Shares Sold by Rhumbline Advisers

Rhumbline Advisers cut its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 7.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 183,212 shares of the company’s stock after selling 15,275 shares during the period. Rhumbline Advisers’ holdings in Vaxcyte were worth $6,599,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of PCVX. Edgestream Partners L.P. bought a new position in shares of Vaxcyte during the second quarter valued at approximately $1,610,000. Federated Hermes Inc. grew its stake in Vaxcyte by 6,856.3% during the 3rd quarter. Federated Hermes Inc. now owns 18,156 shares of the company’s stock worth $654,000 after buying an additional 17,895 shares during the last quarter. State of New Jersey Common Pension Fund D increased its position in Vaxcyte by 36.4% in the second quarter. State of New Jersey Common Pension Fund D now owns 55,477 shares of the company’s stock worth $1,804,000 after buying an additional 14,799 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Vaxcyte in the third quarter valued at $2,640,000. Finally, Quadrature Capital Ltd bought a new stake in Vaxcyte in the second quarter valued at $1,359,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $58.51 on Monday. The stock has a market cap of $7.66 billion, a price-to-earnings ratio of -12.09 and a beta of 1.33. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $84.01. The stock’s 50 day moving average price is $50.05 and its 200 day moving average price is $43.01.

Insiders Place Their Bets

In other news, insider Harpreet S. Dhaliwal sold 9,743 shares of the company’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total value of $454,900.67. Following the completion of the sale, the insider owned 23,928 shares in the company, valued at $1,117,198.32. This represents a 28.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Elvia Cowan sold 11,623 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total value of $556,974.16. Following the transaction, the senior vice president directly owned 14,534 shares of the company’s stock, valued at $696,469.28. This represents a 44.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PCVX. Guggenheim restated a “buy” rating and set a $116.00 price target on shares of Vaxcyte in a research report on Monday, February 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, January 9th. Needham & Company LLC lifted their price target on Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. BTIG Research reiterated a “buy” rating and set a $85.00 price objective on shares of Vaxcyte in a research report on Monday, November 10th. Finally, Leerink Partners set a $77.00 target price on Vaxcyte and gave the company an “outperform” rating in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $93.83.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.